Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%

There is a lack of markers for predicting favorable outcomes after pembrolizumab therapy in patients with non-small cell lung cancer (NSCLC) with programmed death ligand-1 (PD-L1) expression ≥ 50%. This retrospective study examined the prognostic significance of 2-deoxy-2-[18F] fluoro-d-glucose ((18...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Ou, Kaira, Kyoichi, Hashimoto, Kosuke, Mouri, Atsuto, Shiono, Ayako, Miura, Yu, Murayama, Yoshitake, Kobayashi, Kunihiko, Kagamu, Hiroshi, Kuji, Ichiei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490347/
https://www.ncbi.nlm.nih.gov/pubmed/32929123
http://dx.doi.org/10.1038/s41598-020-71735-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490347/
https://www.ncbi.nlm.nih.gov/pubmed/32929123
http://dx.doi.org/10.1038/s41598-020-71735-y

Ejemplares similares